Vaccines, genes and trials

Novartis Foundation Symposium

Volumn , Issue 217, 1998, Pages 57-72

  Fine, Paul E M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; CLINICAL TRIAL; GENETICS; HUMAN; IMMUNOLOGY; LUNG TUBERCULOSIS; MICROBIOLOGY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW;

ADULT; BCG VACCINE; CLINICAL TRIALS; ENVIRONMENTAL MICROBIOLOGY; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 0032234895     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (16)

1. Behr MA, Small PM 1997 Has BCG attenuated to impotence? Nature 389:133-134
2. Bloom BR, Fine PEM 1994 The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR (ed) Tuberculosis: pathogenesis, protection and control. American Society of Microbiology, Washington DC, p 531-557
3. Brahmajothi V, Pitchappan RM, Kakkanaiah VN et al 1991 Association of pulmonary tuberculosis and HLA in South India. Tubercle 72:123-132
4. Brown DH, Miles BA, Zwilling BS 1995 Growth of Mycobacterium tuberculosis in BCG-resistant and susceptible mice: establishment of latency and reactivation Infect Immun 63:2243-2247
5. Comstock GW 1978 Tuberculosis in twins: a reanalysis of the Prophit survey. Am Rev Respir Dis 117:621-624
6. Comstock GW 1988 Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 138:479-480
7. Comstock GW 1994 Field trials of tuberculosis vaccines: how could we have done them better? Controlled Clin Trials 15:247-276
8. Comstock GW, Palmer CE 1966 Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 93:171-183
9. Fine PEM 1981 Immunogenetic aspects of leprosy, tuberculosis and leishmaniasis In: Humber D (ed) Proceedings of AHRI conference on immunology of leprosy, tuberculosis and leishmaniasis. Excerpta Medica, Amsterdam, p 214-222
10. Fine PEM 1993 Immunities in and to tuberculosis: implications for pathogenesis and vaccination. In: Porter JDH, McAdam KPWJ (eds) Tuberculosis: back to the future. John Wiley & Sons Ltd, Chichester, p 53-74
11. Fine PEM 1995 Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345
12. Gambia Hepatitis Study Group 1987 The Gambia hepatitis intervention study. Cancer Res 47:5782-5787
13. Hank JA, Chan JK, Edwards ML, Muller D, Smith DW 1981 Influence of the virulence of Mycobacterium tuberculosis on protection induced by Bacille Calmette-Guérin in guinea-pigs. J Infect Dis 143:734-738
14. Hart PD'A, Sutherland I, Thomas J 1967 The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in tuberculin sensitivity and to technical variations in the vaccines. Tubercle 48:201-210
15. Hermans PWM, Messadi F, Guebrexabher H et al 1995 Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia and the Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis 171:1504-1513
16. Karonga Prevention Trial Group 1996 Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348:17-24